publication date: Aug. 3, 2010
In this issue: ESA Risk Mitigation Strategy Requires Training, Patient Consent, Documentation. FDA Approved More Than 50 New Indications For Cancer In 32 Months, Analysis Finds. FDA Approves Rituxan For CLL. Download PDF
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.